Observational Study on the Long Term Safety of Kuvan® Treatment in Patients With Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or BH4 Deficiency

NCT01016392 · clinicaltrials.gov ↗

COMPLETED

Status

627

Enrollment

INDUSTRY

Sponsor class

Conditions

Hyperphenylalaninemia (HPA) Due to Phenylketonuria (PKU) or Tetrahydrobiopterin (BH4) Deficiency

Sponsor

BioMarin Pharmaceutical